Olivier Bogillot
Vermögen: 27 071 $ am 31.07.2026
Vermögen: 27 071 $ am 31.07.2026
Olivier Bogillot is currently Chairman at Sanofi Pasteur Merieux SAS since 2020.
Formerly, Dr. Bogillot was Chairman & Chief Executive Officer at Sanofi-Aventis France SA and President & Director at Provention Bio, Inc. Dr. Bogillot earned a doctorate from the University of Lyon.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2025 | 5’897 ( 0% ) | 27 071 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CLARIANE SE | Direktor/Vorstandsmitglied | 14.05.2025 |
Sanofi Pasteur Merieux SAS
Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Engages in activities of holding companies | Vorsitzender | 01.03.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Vorstandsvorsitzender | - |
| PROVENTION BIO, INC. | Präsident | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Clariane SE
Clariane SE Medical/Nursing ServicesHealth Services Operates retirement homes | Health Services |
University of Lyon
University of Lyon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Pasteur Merieux SAS
Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Engages in activities of holding companies | Finance |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Provention Bio, Inc.
Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company that engages in intercepting and preventing immune-mediated diseases including type 1 diabetic activities | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen